Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Cobenfy"

4 News Found

Bristol Myers Squibb reports positive phase 4 data on Cobenfy for schizophrenia patients
News | March 31, 2026

Bristol Myers Squibb reports positive phase 4 data on Cobenfy for schizophrenia patients

The open-label trial involved 105 adults with schizophrenia who were on a stable dose of an oral atypical antipsychotic for at least six weeks


Bristol Myers to extend key trial of Cobenfy in Alzheimer’s psychosis
Clinical Trials | December 04, 2025

Bristol Myers to extend key trial of Cobenfy in Alzheimer’s psychosis

The company is excluding data from the affected sites to maintain the study's integrity


BMS’ Cobenfy sees steady start, eyes stronger growth ahead
News | October 31, 2025

BMS’ Cobenfy sees steady start, eyes stronger growth ahead

Cobenfy generated $43 million in third-quarter sales, up from $35 million in the second quarter


FDA approves Bristol Myers Squibb’s Cobenfy
Drug Approval | September 28, 2024

FDA approves Bristol Myers Squibb’s Cobenfy

A first-in-class muscarinic agonist for the treatment of schizophrenia in adults